drugset / Trial / NCT01786018
Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate progression free survival, transplant-related morbidity (TRM) at day +100 and at +365, overall survival and incidence of acute and chronic GVHD in refractory/early relapsed aggressive B-cell non Hodgkin lymphomas patients treated with allogeneic Transplantation after a conditioning with Thiotepa, Busulfan and fludarabin.
Timeline
- Start
- 2013-02
- Primary completion
- 2015-02
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | ATG | Unknown | 2.5 mg/kg | — |
| Background | Busulfan | Small molecule | 3.2 mg/kg | Intravenous |
| Background | Cyclosporine | Peptide | 5 mg/kg | Oral |
| Background | Fludarabin | Unknown | 50 mg/m2 | — |
| Background | Methotrexate | Small molecule | 10 mg/m2 | Intravenous |
| Background | Thiotepa | Other / unclassified | 5 mg/kg | — |